Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
When a company obtains positive news from the Food and Drug Administration (FDA), such as the approval of a treatment or a label expansion, it can mark a milestone for the business and lead to significant revenue growth. The risk with many biotech stocks is not knowing if they will obtain approval for a key treatment, or if that approval might come with an asterisk and only cover certain aspects of an illness or condition.
Sarepta Therapeutics (NASDAQ: SRPT) stock has been flying of late, as the company got some great news from the FDA that has the potential to be a game changer for its business. Investors are bullish on the developments. Here's a look at the details and what they mean for the company.
Last year, the FDA granted accelerated approval for Sarepta's gene therapy treatment, Elevidys, as a treatment for Duchenne muscular dystrophy (DMD) in children between the ages of 4 and 5. That was bittersweet for investors because while it was an approval, its scope was narrow, and the company was hoping for a broader indication.
Source Fool.com
Sarepta Therapeutics Stock
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Sarepta Therapeutics stock is not clear.
However, we have a potential of -4.45% for Sarepta Therapeutics as the target price of 130 € is below the current price of 136.05 €.
